Repurposed Drugs in Gastric Cancer.
Diana AraújoEduarda RibeiroIrina AmorimNuno ValePublished in: Molecules (Basel, Switzerland) (2022)
Gastric cancer (GC) is one of the major causes of death worldwide, ranking as the fifth most incident cancer in 2020 and the fourth leading cause of cancer mortality. The majority of GC patients are in an advanced stage at the time of diagnosis, presenting a poor prognosis and outcome. Current GC treatment approaches involve endoscopic detection, gastrectomy and chemotherapy or chemoradiotherapy in an adjuvant or neoadjuvant setting. Drug development approaches demand extreme effort to identify molecular mechanisms of action of new drug candidates. Drug repurposing is based on the research of new therapeutic indications of drugs approved for other pathologies. In this review, we explore GC and the different drugs repurposed for this disease.
Keyphrases
- poor prognosis
- locally advanced
- papillary thyroid
- rectal cancer
- long non coding rna
- end stage renal disease
- gas chromatography
- squamous cell
- chronic kidney disease
- ejection fraction
- newly diagnosed
- cardiovascular disease
- squamous cell carcinoma
- early stage
- lymph node
- climate change
- adverse drug
- lymph node metastasis
- mass spectrometry
- type diabetes
- case report
- patient reported outcomes
- coronary artery disease
- young adults
- combination therapy